Sign in

Jacob M. Chacko, M.D.

President and Chief Executive Officer at Oric Pharmaceuticals
Since May 2018
Age
45 years
Education
Holds a B.A. in Biology and a B.S. in Gerontology from the University of Southern California, an M.D. from the University of California, Los Angeles, an M.B.A. from Harvard Business School, and an M.Sc. from Oxford University.
Tenure
Joined ORIC in May 2018 as Chief Executive Officer and was promoted to President in May 2019, driving key advancements and strategic growth at the company.

Also at Oric Pharmaceuticals

DP
Dominic Piscitelli
Chief Financial Officer

About

Dr. Jacob M. Chacko, M.D. has played a pivotal role at ORIC Pharmaceuticals since joining the company in May 2018 as Chief Executive Officer, a position that reflects his extensive expertise in the biotechnology and healthcare sectors.

He built a formidable academic profile by earning advanced degrees from top-tier institutions, including a B.A. in Biology and a B.S. in Gerontology from the University of Southern California, an M.D. from the University of California, Los Angeles, an M.B.A. from Harvard Business School, and an M.Sc. from Oxford University.

Prior to his tenure at ORIC, he held significant roles such as Chief Financial Officer at Ignyta, Inc., where he contributed during its acquisition by Roche, and served as Vice President at TPG Capital, alongside providing consultancy services at McKinsey & Company. His diverse experience has underpinned ORIC's strategic initiatives, including advancing clinical programs and securing substantial financing to extend the company's growth trajectory.

$ORIC Performance Under Jacob M. Chacko, M.D.

Past Roles

Organization Role Date Range Details
Ignyta, Inc. Chief Financial Officer May 2014 - February 2018 Acquired by Roche Holding AG in February 2018
TPG Capital Vice President August 2008 - May 2014 Private equity investment firm
McKinsey & Company Consultant to Healthcare Clients N/A No specific dates provided
Turning Point Therapeutics Board Member N/A Past board role
Bonti, Inc. Board Member N/A Past board role

External Roles

Organization Role Date Range Details
Bright Peak Therapeutics, Inc. Chair of the Board of Directors Since November 2021 Private biotechnology company
4D Molecular Therapeutics, Inc. Member of the Board of Directors Since March 2019 Public clinical-stage biotechnology company

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Salary$596,083 N/A Fixed annual salary for 2023
All Other Compensation$14,720 N/A Breakdown: 401(k) matching contributions: $11,800; Life insurance premiums: $2,920

Performance Compensation

Data from  FY 2023

No information available on performance compensation for 2023.